Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2014 / Jan / Keeping an Eye on Diabetes
Research & Innovations

Keeping an Eye on Diabetes

Transplanting pancreatic Islets of Langerhans into the ocular anterior chamber of the eye allows researchers to effectively monitor β-cell function.

By Mark Hillen 1/20/2014 1 min read

Share

When the demand for insulin is high – such as during prolonged periods of excess food consumption or when insulin resistance occurs – the number of β cells increases. This plasticity is essential for normal blood sugar levels to be maintained; diabetes results from its dysfunction.

Assessing the state of β-cells in vivo would provide valuable information on the function of the cells and on disease state of patients with insulin resistance or diabetes. However, it is difficult to assess these cells, given their location: non-invasive imaging techniques like ultrasound or magnetic resonance imaging are inadequate, and biopsies are invasive and give only a snapshot of what’s going on. Now, a new approach has been proposed by Per-Olof Berggren, a Professor of Experimental Endocrinology at Sweden’s Karolinska Institutet and Erwin Ilegems,  researcher at the Rolf Luft Research Centre for Diabetes and Endocrinology, and their colleagues. Their solution is to transplant Islets of Langerhans into the anterior chamber of the eye. The work, for now, is being conducted in mice (1).

“We’ve made the cells optically accessible by grafting a small number of ‘reporter islets’ into the eyes of mice, which allows us to monitor the activity of the pancreas just by looking into the eye,” says Berggren. “We’re now able to really study the insulin-producing β-cells in detail in a way that wasn’t possible before.” “The transplanted islets can be visualized repeatedly over a period of months. During this time, the functional and morphological changes that occur in them that are identical to those occurring in the pancreas,” says Ilegems.

“We’ll be using the system to identify new drug substances that regulate β-cell plasticity and function,” Berggren adds. “In the future we may develop reporter islets in humans in order to find unique, tailored treatment principles, to measure the effects of personal medication, or to diagnose problems with the pancreatic islets.” So don’t be too surprised when you perform ophthalmoscopy in a decade’s time if you see bits of the body that shouldn’t really be there. The principle may also work with other cell types too – so it may be that a whole diagnostic panel of disease-marking cells could await your examination.

References

  1. E Ilegems, A Dicker, S Speier, et al., “Reporter islets in the eye reveal plasticity of the endocrine pancreas”, PNAS, Epub ahead of print.

About the Author(s)

Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

More Articles by Mark Hillen

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: